Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
企業コードVRAX
会社名Virax Biolabs Group Ltd
上場日Jul 14, 2022
最高経営責任者「CEO」Mr. James Foster
従業員数19
証券種類Ordinary Share
決算期末Jul 14
本社所在地Biocity Glasgow
都市LONDON
証券取引所NASDAQ Capital Market Consolidated
国United Kingdom
郵便番号ML1 5UH
電話番号4402077887414
ウェブサイトhttps://www.viraxbiolabs.com
企業コードVRAX
上場日Jul 14, 2022
最高経営責任者「CEO」Mr. James Foster
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし